CUAJ, E. (2026) “Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients with Urological Cancers – Adverse Events (AEs): Management Tool Kit”, Canadian Urological Association Journal, 15(1X). Available at: https://cuaj.ca/index.php/journal/article/view/9883 (Accessed: 31 May 2026).